Streptococcus pneumoniae: Epidemiology, Risk Factors, and Strategies for Prevention

ABSTRACT

Streptococcus pneumoniae is the most common cause of community-acquired pneumonia, meningitis, and bacteremia in children and adults. Invasive pneumococcal disease (IPD) primarily affects young children, older adults (> 65 years of age), and individuals with comorbidities or impaired immune systems. Case fatality rates range from 10 to 30% in adults with IPD but are much lower (< 3%) in children. In this article, we describe the epidemiology of IPD, risk factors, and the influence of host- and organism-specific factors on outcomes. Most cases of IPD are caused by a limited number of serotypes that vary in infectivity and virulence. Vaccinating adults and high-risk patients with the pneumococcal polysaccharide vaccine reduces the incidence of IPD in populations at risk but does not affect nasopharyngeal colonization and has had limited benefit in the population at large. Use of the heptavalent pneumococcal conjugate vaccine (PCV7) in children in the United States since 2000 has resulted in a substantial decline of IPD in both children and adults (by herd immunity), but has facilitated the emergence of serotypes not encompassed in the PCV7 vaccine. Recent reports of “replacement” serotypes that have heightened virulence are worrisome. In this chapter, we discuss the role of vaccines (both polysaccharide and conjugate) and other preventive strategies to limit this important and potentially lethal disease.

KEYWORDS

Streptococcus pneumoniae - pneumococcus - invasive pneumococcal disease - pneumococcal vaccine - pneumococcal conjugate vaccine - serotypes

REFERENCES

• 1 Ortqvist A, Hedlund J, Kalin M. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features.  Semin Respir Crit Care Med. 2005;  26 563-574
• 2 Kalin M, Ortqvist A, Almela M et al.. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries.  J Infect Dis. 2000;  182 840-847
• 3 Fang G D, Fine M, Orloff J et al.. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases.  Medicine (Baltimore). 1990;  69 307-316
• 4 Bartlett J G, Mundy L M. Community-acquired pneumonia.  N Engl J Med. 1995;  333 1618-1624
• 5 Yu V L, Chiou C C, Feldman C et al.. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome.  Clin Infect Dis. 2003;  37 230-237
• 6 Musher D M, Alexandraki I, Graviss E A et al.. Bacteremic and nonbacteremic pneumococcal pneumonia: a prospective study.  Medicine (Baltimore). 2000;  79 210-221
• 7 Shah S S, Ratner A J. Trends in invasive pneumococcal disease-associated hospitalizations.  Clin Infect Dis. 2006;  42 e1-e5
• 8 Schuchat A, Robinson K, Wenger J D et al.. Bacterial meningitis in the United States in 1995. Active Surveillance Team.  N Engl J Med. 1997;  337 970-976
• 9 Klein J O. Otitis media.  Clin Infect Dis. 1994;  19 823-833
• 10 Musher D M, Montoya R, Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia.  Clin Infect Dis. 2004;  39 165-169
• 11 Mufson M A, Stanek R J. Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978–1997.  Am J Med. 1999;  107(1A) 34S-43S
• 12 Watanakunakorn C, Greifenstein A, Stroh K et al.. Pneumococcal bacteremia in three community teaching hospitals from 1980 to 1989.  Chest. 1993;  103 1152-1156
• 13 Mufson M A, Kruss D M, Wasil R E, Metzger W I. Capsular types and outcome of bacteremic pneumococcal disease in the antibiotic era.  Arch Intern Med. 1974;  134 505-510
• 14 Pallares R, Linares J, Vadillo M et al.. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.  N Engl J Med. 1995;  333 474-480
• 15 Alanee S R, McGee L, Jackson D et al.. Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study.  Clin Infect Dis. 2007;  45 46-51
• 16 Ortqvist A. Pneumococcal disease in Sweden: experiences and current situation.  Am J Med. 1999;  107(1A) 44S-49S
• 17 Robinson K A, Baughman W, Rothrock G et al.. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: opportunities for prevention in the conjugate vaccine era.  JAMA. 2001;  285 1729-1735
• 18 Kaplan S L, Mason Jr E O, Wald E et al.. Six year multicenter surveillance of invasive pneumococcal infections in children.  Pediatr Infect Dis J. 2002;  21 141-147
• 19 Schuchat A, Broome C V, Hightower A, Costa S J, Parkin W. Use of surveillance for invasive pneumococcal disease to estimate the size of the immunosuppressed HIV-infected population.  JAMA. 1991;  265 3275-3279
• 20 Lynch III J P, Zhanel G G. Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy.  Semin Respir Crit Care Med. 2005;  26 575-616
• 21 Pneumococcal conjugate vaccine for childhood immunization–WHO position paper.  Wkly Epidemiol Rec. 2007;  82 93-104
• 22 Scott J A. The preventable burden of pneumococcal disease in the developing world.  Vaccine. 2007;  25 2398-2405
• 23 Whitney C G, Farley M M, Hadler J et al.. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.  N Engl J Med. 2003;  348 1737-1746
• 24 Jefferson T, Ferroni E, Curtale F, Giorgi Rossi P, Borgia P. Streptococcus pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years old.  Lancet Infect Dis. 2006;  6 405-410
• 25 Flamaing J, Verhaegen J, Peetermans W E. Streptococcus pneumoniae bacteraemia in Belgium: differential characteristics in children and the elderly population and implications for vaccine use.  J Antimicrob Chemother. 2002;  50 43-50
• 26 Diez-Domingo J, Pereiro I, Morant A et al.. Epidemiology of invasive Streptococcus pneumoniae infections in children in Spain, 1996–1998.  J Infect. 2002;  45 139-143
• 27 Konradsen H B, Kaltoft M S. Invasive pneumococcal infections in Denmark from 1995 to 1999: epidemiology, serotypes, and resistance.  Clin Diagn Lab Immunol. 2002;  9 358-365
• 28 Breiman R F, Spika J S, Navarro V J, Darden P M, Darby C P. Pneumococcal bacteremia in Charleston County, South Carolina: a decade later.  Arch Intern Med. 1990;  150 1401-1405
• 29 Hedlund J, Svenson S B, Kalin M et al.. Incidence, capsular types, and antibiotic susceptibility of invasive Streptococcus pneumoniae in Sweden.  Clin Infect Dis. 1995;  21 948-953
• 30 Henriques Normark B, Kalin M, Ortqvist A et al.. Dynamics of penicillin-susceptible clones in invasive pneumococcal disease.  J Infect Dis. 2001;  184 861-869
• 31 Magnus T, Andersen B M. Serotypes and resistance patterns of Streptococcus pneumoniae causing systemic disease in northern Norway.  Eur J Clin Microbiol Infect Dis. 1995;  14 229-234
• 32 Nielsen S V, Henrichsen J. Incidence of invasive pneumococcal disease and distribution of capsular types of pneumococci in Denmark, 1989–94.  Epidemiol Infect. 1996;  117 411-416
• 33 Hsu K, Pelton S, Karumuri S, Heisey-Grove D, Klein J. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine.  Pediatr Infect Dis J. 2005;  24 17-23
• 34 Haddy R I, Perry K, Chacko C E et al.. Comparison of incidence of invasive Streptococcus pneumoniae disease among children before and after introduction of conjugated pneumococcal vaccine.  Pediatr Infect Dis J. 2005;  24 320-323
• 35 Talbot T R, Poehling K A, Hartert T V et al.. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine.  Clin Infect Dis. 2004;  39 641-648
• 36 Kaplan S L, Mason Jr E O, Wald E R et al.. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine.  Pediatrics. 2004;  113(3 Pt 1) 443-449
• 37 Bender J M, Ampofo K, Korgenski K et al.. Pneumococcal necrotizing pneumonia in Utah: does serotype matter?.  Clin Infect Dis. 2008;  46 1346-1352
• 38 Gonzalez B E, Hulten K G, Lamberth L, Kaplan S L, Mason Jr E O. Streptococcus pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine.  Pediatr Infect Dis J. 2006;  25 301-305
• 39 Regev-Yochay G, Raz M, Dagan R et al.. Nasopharyngeal carriage of Streptococcus pneumoniae by adults and children in community and family settings.  Clin Infect Dis. 2004;  38 632-639
• 40 Shimada J, Yamanaka N, Hotomi M et al.. Household transmission of Streptococcus pneumoniae among siblings with acute otitis media.  J Clin Microbiol. 2002;  40 1851-1853
• 41 Gwaltney Jr J M. Acute community-acquired sinusitis.  Clin Infect Dis. 1996;  23 1209-1223 quiz 1224-1225
• 42 Martin M, Turco J H, Zegans M E et al.. An outbreak of conjunctivitis due to atypical Streptococcus pneumoniae .  N Engl J Med. 2003;  348 1112-1121
• 43 Crum N F, Barrozo C P, Chapman F A, Ryan M A, Russell K L. An outbreak of conjunctivitis due to a novel unencapsulated Streptococcus pneumoniae among military trainees.  Clin Infect Dis. 2004;  39 1148-1154
• 44 Byington C L, Spencer L Y, Johnson T A et al.. An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations.  Clin Infect Dis. 2002;  34 434-440
• 45 Hsieh Y C, Hsueh P R, Lu C Y, Lee P I, Lee C Y, Huang L M. Clinical manifestations and molecular epidemiology of necrotizing pneumonia and empyema caused by Streptococcus pneumoniae in children in Taiwan.  Clin Infect Dis. 2004;  38 830-835
• 46 Hardie W, Bokulic R, Garcia V F, Reising S F, Christie C D. Pneumococcal pleural empyemas in children.  Clin Infect Dis. 1996;  22 1057-1063
• 47 Byington C L, Korgenski K, Daly J, Ampofo K, Pavia A, Mason E O. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema.  Pediatr Infect Dis J. 2006;  25 250-254
• 48 Stanek R J, Mufson M A. A 20-year epidemiological study of pneumococcal meningitis.  Clin Infect Dis. 1999;  28 1265-1272
• 49 Givner L B, Mason Jr E O, Tan T Q et al.. Pneumococcal endocarditis in children.  Clin Infect Dis. 2004;  38 1273-1278
• 50 Martinez E, Miro J M, Almirante B et al.. Effect of penicillin resistance of Streptococcus pneumoniae on the presentation, prognosis, and treatment of pneumococcal endocarditis in adults.  Clin Infect Dis. 2002;  35 130-139
• 51 Lefort A, Mainardi J L, Selton-Suty C, Casassus P, Guillevin L, Lortholary O. Streptococcus pneumoniae endocarditis in adults: a multicenter study in France in the era of penicillin resistance (1991–1998). The Pneumococcal Endocarditis Study Group.  Medicine (Baltimore). 2000;  79 327-337
• 52 Ispahani P, Weston V C, Turner D P, Donald F E. Septic arthritis due to Streptococcus pneumoniae in Nottingham, United Kingdom, 1985–1998.  Clin Infect Dis. 1999;  29 1450-1454
• 53 Capdevila O, Grau I, Vadillo M, Cisnal M, Pallares R. Bacteremic pneumococcal cellulitis compared with bacteremic cellulitis caused by Staphylococcus aureus and Streptococcus pyogenes .  Eur J Clin Microbiol Infect Dis. 2003;  22 337-341
• 54 McEllistrem M C, Mendelsohn A B, Pass M A et al.. Recurrent invasive pneumococcal disease in individuals with human immunodeficiency virus infection.  J Infect Dis. 2002;  185 1364-1368
• 55 Albrich W C, Baughman W, Schmotzer B, Farley M M. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine.  Clin Infect Dis. 2007;  44 1569-1576
• 56 Sjostrom K, Spindler C, Ortqvist A et al.. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen.  Clin Infect Dis. 2006;  42 451-459
• 57 Lexau C A, Lynfield R, Danila R et al.. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine.  JAMA. 2005;  294 2043-2051
• 58 Bogaert D, De Groot R, Hermans P W. Streptococcus pneumoniae colonisation: the key to pneumococcal disease.  Lancet Infect Dis. 2004;  4 144-154
• 59 Regev-Yochay G, Raz M, Shainberg B et al.. Independent risk factors for carriage of penicillin-non-susceptible Streptococcus pneumoniae .  Scand J Infect Dis. 2003;  35 219-222
• 60 Syrogiannopoulos G A, Grivea I N, Beratis N G et al.. Resistance patterns of Streptococcus pneumoniae from carriers attending day-care centers in southwestern Greece.  Clin Infect Dis. 1997;  25 188-194
• 61 Syrogiannopoulos G A, Katopodis G D, Grivea I N, Beratis N G. Antimicrobial use and serotype distribution of nasopharyngeal Streptococcus pneumoniae isolates recovered from Greek children younger than 2 years old.  Clin Infect Dis. 2002;  35 1174-1182
• 62 Hussain M, Melegaro A, Pebody R G et al.. A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting.  Epidemiol Infect. 2005;  133 891-898
• 63 Nunes S, Sa-Leao R, Carrico J et al.. Trends in drug resistance, serotypes, and molecular types of Streptococcus pneumoniae colonizing preschool-age children attending day care centers in Lisbon, Portugal: a summary of 4 years of annual surveillance.  J Clin Microbiol. 2005;  43 1285-1293
• 64 Greenberg D, Givon-Lavi N, Broides A, Blancovich I, Peled N, Dagan R. The contribution of smoking and exposure to tobacco smoke to Streptococcus pneumoniae and Haemophilus influenzae carriage in children and their mothers.  Clin Infect Dis. 2006;  42 897-903
• 65 Cardozo D M, Nascimento-Carvalho C M, Andrade A L et al.. Prevalence and risk factors for nasopharyngeal carriage of Streptococcus pneumoniae among adolescents.  J Med Microbiol. 2008;  57(Pt 2) 185-189
• 66 Brooks K J, Paschane D M, Fisher D G, Orr S M. Pneumococcal carriage in an Alaskan drug-using population.  Int J Circumpolar Health. 1998;  57(Suppl 1) 260-264
• 67 Hansman D, Morris S, Gregory M, McDonald B. Pneumococcal carriage amongst Australian aborigines in Alice Springs, Northern Territory.  J Hyg (Lond). 1985;  95 677-684
• 68 Nuorti J P, Butler J C, Crutcher J M et al.. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents.  N Engl J Med. 1998;  338 1861-1868
• 69 Hoshino K, Watanabe H, Sugita R et al.. High rate of transmission of penicillin-resistant Streptococcus pneumoniae between parents and children.  J Clin Microbiol. 2002;  40 4357-4359
• 70 Muhlemann K, Matter H C, Tauber M G, Bodmer T. Nationwide surveillance of nasopharyngeal Streptococcus pneumoniae isolates from children with respiratory infection, Switzerland, 1998–1999.  J Infect Dis. 2003;  187 589-596
• 71 Haddad M B, Porucznik C A, Joyce K E et al.. Risk factors for pediatric invasive pneumococcal disease in the Intermountain West, 1996–2002.  Ann Epidemiol. 2008;  18 139-146
• 72 Tuomanen E I, Austrian R, Masure H R. Pathogenesis of pneumococcal infection.  N Engl J Med. 1995;  332 1280-1284
• 73 Flannery B, Heffernan R T, Harrison L H et al.. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization.  Ann Intern Med. 2006;  144 1-9
• 74 Flannery B, Schrag S, Bennett N M et al.. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections.  JAMA. 2004;  291 2197-2203
• 75 Hjuler T, Poulsen G, Wohlfahrt J, Kaltoft M, Biggar R J, Melbye M. Genetic susceptibility to severe infection in families with invasive pneumococcal disease.  Am J Epidemiol. 2008;  167 814-819
• 76 Kyaw M H, Rose Jr C E, Fry A M et al.. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults.  J Infect Dis. 2005;  192 377-386
• 77 Pallares R, Gudiol F, Linares J et al.. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci.  N Engl J Med. 1987;  317 18-22
• 78 High K P. Pneumonia in older adults: new categories add complexity to diagnosis and care.  Postgrad Med. 2005;  118 18-20 25-28
• 79 Butler J C, Schuchat A. Epidemiology of pneumococcal infections in the elderly.  Drugs Aging. 1999;  15(Suppl 1) 11-19
• 80 Weinberger D M, Dagan R, Givon-Lavi N, Regev-Yochay G, Malley R, Lipsitch M. Epidemiologic evidence for serotype-specific acquired immunity to pneumococcal carriage.  J Infect Dis. 2008;  197 1511-1518
• 81 Quinton L, Happel K, Gamble L, Nelson S. Pulmonary host defense: basic mechanisms and strategies for immunomodulation. In: Niederman MS Severe Pneumonia: Lung Biology in Health and Science. Boca Raton; Taylor and Francis 2005: 383-411
• 82 Millar E V, O'Brien K L, Bronsdon M A et al.. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine.  Clin Infect Dis. 2007;  44 1173-1179
• 83 Malley R, Lipsitch M, Bogaert D et al.. Serum antipneumococcal antibodies and pneumococcal colonization in adults with chronic obstructive pulmonary disease.  J Infect Dis. 2007;  196 928-935
• 84 Goldblatt D, Hussain M, Andrews N et al.. Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study.  J Infect Dis. 2005;  192 387-393
• 85 Kirby A C, Raynes J G, Kaye P M. The role played by tumor necrosis factor during localized and systemic infection with Streptococcus pneumoniae .  J Infect Dis. 2005;  191 1538-1547
• 86 O'Brien D P, Briles D E, Szalai A J, Tu A H, Sanz I, Nahm M H. Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infections.  Infect Immun. 1999;  67 595-601
• 87 Lauw F N, Branger J, Florquin S et al.. IL-18 improves the early antimicrobial host response to pneumococcal pneumonia.  J Immunol. 2002;  168 372-378
• 88 Koedel U, Angele B, Rupprecht T et al.. Toll-like receptor 2 participates in mediation of immune response in experimental pneumococcal meningitis.  J Immunol. 2003;  170 438-444
• 89 Haraguchi S, Day N K, Nelson Jr R P et al.. Interleukin 12 deficiency associated with recurrent infections.  Proc Natl Acad Sci U S A. 1998;  95 13125-13129
• 90 Picard C, Puel A, Bustamante J, Ku C L, Casanova J L. Primary immunodeficiencies associated with pneumococcal disease.  Curr Opin Allergy Clin Immunol. 2003;  3 451-459
• 91 Kruetzmann S, Rosado M M, Weber H et al.. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen.  J Exp Med. 2003;  197 939-945
• 92 Henriques B, Kalin M, Ortqvist A et al.. Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries.  J Infect Dis. 2000;  182 833-839
• 93 Martens P, Worm S W, Lundgren B, Konradsen H B, Benfield T. Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited.  BMC Infect Dis. 2004;  4 21
• 94 Scott J A, Hall A J, Dagan R et al.. Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease.  Clin Infect Dis. 1996;  22 973-981
• 95 Sandgren A, Sjostrom K, Olsson-Liljequist B et al.. Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumoniae .  J Infect Dis. 2004;  189 785-796
• 96 Butler J C, Breiman R F, Lipman H B, Hofmann J, Facklam R R. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978–1994: implications for development of a conjugate vaccine.  J Infect Dis. 1995;  171 885-889
• 97 Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention.  Rev Infect Dis. 1981;  3(Suppl) S1-S17
• 98 Verhaegen J, Glupczynski Y, Verbist L et al.. Capsular types and antibiotic susceptibility of pneumococci isolated from patients in Belgium with serious infections, 1980–1993.  Clin Infect Dis. 1995;  20 1339-1345
• 99 Gonzalez B E, Hulten K G, Kaplan S L, Mason Jr E O. Clonality of Streptococcus pneumoniae serotype 1 isolates from pediatric patients in the United States.  J Clin Microbiol. 2004;  42 2810-2812
• 100 Toltzis P, Dul M, O'Riordan M A, Jacobs M R, Blumer J. Serogroup 19 pneumococci containing both mef and erm macrolide resistance determinants in an American city.  Pediatr Infect Dis J. 2006;  25 19-24
• 101 Kyaw M H, Lynfield R, Schaffner W et al.. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae .  N Engl J Med. 2006;  354 1455-1463
• 102 Pai R, Moore M R, Pilishvili T, Gertz R E, Whitney C G, Beall B. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States.  J Infect Dis. 2005;  192 1988-1995
• 103 Messina A F, Katz-Gaynor K, Barton T et al.. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005.  Pediatr Infect Dis J. 2007;  26 461-467
• 104 Pelton S I, Huot H, Finkelstein J A et al.. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine.  Pediatr Infect Dis J. 2007;  26 468-472
• 105 Sleeman K L, Griffiths D, Shackley F et al.. Capsular serotype-specific attack rates and duration of carriage of Streptococcus pneumoniae in a population of children.  J Infect Dis. 2006;  194 682-688
• 106 Brueggemann A B, Peto T E, Crook D W, Butler J C, Kristinsson K G, Spratt B G. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children.  J Infect Dis. 2004;  190 1203-1211
• 107 Brueggemann A B, Griffiths D T, Meats E, Peto T, Crook D W, Spratt B G. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential.  J Infect Dis. 2003;  187 1424-1432
• 108 McKenzie H, Reid N, Dijkhuizen R S. Clinical and microbiological epidemiology of Streptococcus pneumoniae bacteraemia.  J Med Microbiol. 2000;  49 361-366
• 109 Sandgren A, Albiger B, Orihuela C J, Tuomanen E, Normark S, Henriques-Normark B. Virulence in mice of pneumococcal clonal types with known invasive disease potential in humans.  J Infect Dis. 2005;  192 791-800
• 110 Linares J, Pallares R, Alonso T et al.. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979–1990).  Clin Infect Dis. 1992;  15 99-105
• 111 Feikin D R, Klugman K P. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines.  Clin Infect Dis. 2002;  35 547-555
• 112 Munoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia J J, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine.  Clin Infect Dis. 2008;  46 174-182
• 113 Normark B H, Ortqvist A, Kalin M et al.. Changes in serotype distribution may hamper efficacy of pneumococcal conjugate vaccines in children.  Scand J Infect Dis. 2001;  33 848-850
• 114 Hava D L, Camilli A. Large-scale identification of serotype 4 Streptococcus pneumoniae virulence factors.  Mol Microbiol. 2002;  45 1389-1406
• 115 Hjuler T, Wohlfahrt J, Simonsen J et al.. Perinatal and crowding-related risk factors for invasive pneumococcal disease in infants and young children: a population-based case-control study.  Clin Infect Dis. 2007;  44 1051-1056
• 116 Singleton R J, Butler J C, Bulkow L R et al.. Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska native adults.  Vaccine. 2007;  25 2288-2295
• 117 Mufson M A, Stanek R J. Epidemiology of invasive Streptococcus pneumoniae infections and vaccine implications among children in a West Virginia community, 1978–2003.  Pediatr Infect Dis J. 2004;  23 779-781
• 118 Cherian T, Steinhoff M C, Harrison L H, Rohn D, McDougal L K, Dick J. A cluster of invasive pneumococcal disease in young children in child care.  JAMA. 1994;  271 695-697
• 119 Reichler M R, Rakovsky J, Slacikova M et al.. Spread of multidrug-resistant Streptococcus pneumoniae among hospitalized children in Slovakia.  J Infect Dis. 1996;  173 374-379
• 120 Leino T, Auranen K, Jokinen J, Leinonen M, Tervonen P, Takala A K. Pneumococcal carriage in children during their first two years: important role of family exposure.  Pediatr Infect Dis J. 2001;  20 1022-1027
• 121 Pereiro I, Diez-Domingo J, Segarra L, Ballester A, Albert A, Morant A. Risk factors for invasive disease among children in Spain.  J Infect. 2004;  48 320-329
• 122 Musher D M. Pneumococcal outbreaks in nursing homes.  N Engl J Med. 1998;  338 1915-1916
• 123 Mannheimer S B, Riley L W, Roberts R B. Association of penicillin-resistant pneumococci with residence in a pediatric chronic care facility.  J Infect Dis. 1996;  174 513-519
• 124 Kupronis B A, Richards C L, Whitney C G. Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community.  J Am Geriatr Soc. 2003;  51 1520-1525
• 125 Dagan R, Gradstein S, Belmaker I et al.. An outbreak of Streptococcus pneumoniae serotype 1 in a closed community in southern Israel.  Clin Infect Dis. 2000;  30 319-321
• 126 Gray G C, Mitchell B S, Tueller J E, Cross E R, Amundson D E. Pneumonia hospitalizations in the US Navy and Marine Corps: rates and risk factors for 6,522 admissions, 1981–1991.  Am J Epidemiol. 1994;  139 793-802
• 127 Mercat A, Nguyen J, Dautzenberg B. An outbreak of pneumococcal pneumonia in two men's shelters.  Chest. 1991;  99 147-151
• 128 Hoge C W, Reichler M R, Dominguez E A et al.. An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail.  N Engl J Med. 1994;  331 643-648
• 129 Canet J J, Juan N, Xercavins M, Freixas N, Garau J. Hospital-acquired pneumococcal bacteremia.  Clin Infect Dis. 2002;  35 697-702
• 130 Rubins J B, Cheung S, Carson P, Rubins H B, Janoff E N. Identification of clinical risk factors for nosocomial pneumococcal bacteremia.  Clin Infect Dis. 1999;  29 178-183
• 131 Buie K A, Klugman K P, von Gottberg A et al.. Gender as a risk factor for both antibiotic resistance and infection with pediatric serogroups/serotypes, in HIV-infected and -uninfected adults with pneumococcal bacteremia.  J Infect Dis. 2004;  189 1996-2000
• 132 Valenzuela M T, Altuzarra R H, Trucco O A et al.. Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in elderly residents of a long-term care facility.  Braz J Infect Dis. 2007;  11 322-326
• 133 Holmlund E, Quiambao B, Ollgren J, Nohynek H, Kayhty H. Development of natural antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A and pneumolysin in Filipino pregnant women and their infants in relation to pneumococcal carriage.  Vaccine. 2006;  24 57-65
• 134 Obaro S K, Deubzer H E, Newman V O, Adegbola R A, Greenwood B M, Henderson D C. Serotype-specific pneumococcal antibodies in breast milk of Gambian women immunized with a pneumococcal polysaccharide vaccine during pregnancy.  Pediatr Infect Dis J. 2004;  23 1023-1029
• 135 Kyaw M H, Christie P, Clarke S C et al.. Invasive pneumococcal disease in Scotland, 1999–2001: use of record linkage to explore associations between patients and disease in relation to future vaccination policy.  Clin Infect Dis. 2003;  37 1283-1291
• 136 Gessner B D, Ussery X T, Parkinson A J, Breiman R F. Risk factors for invasive disease caused by Streptococcus pneumoniae among Alaska native children younger than two years of age.  Pediatr Infect Dis J. 1995;  14 123-128
• 137 Singleton R J, Hennessy T W, Bulkow L R et al.. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage.  JAMA. 2007;  297 1784-1792
• 138 Bruce M G, Deeks S L, Zulz T et al.. International Circumpolar Surveillance System for invasive pneumococcal disease, 1999–2005.  Emerg Infect Dis. 2008;  14 25-33
• 139 Christiansen J, Poulsen P, Ladefoged K. Invasive pneumococcal disease in Greenland.  Scand J Infect Dis. 2004;  36 325-329
• 140 Millar E V, O'Brien K L, Watt J P et al.. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population.  Clin Infect Dis. 2006;  43 8-15
• 141 Watt J P, O'Brien K L, Benin A L et al.. Invasive pneumococcal disease among Navajo adults, 1989–1998.  Clin Infect Dis. 2004;  38 496-501
• 142 Watt J P, O'Brien K L, Benin A L et al.. Risk factors for invasive pneumococcal disease among Navajo adults.  Am J Epidemiol. 2007;  166 1080-1087
• 143 Roche P, Krause V. Invasive pneumococcal disease in Australia, 2001.  Commun Dis Intell. 2002;  26 505-519
• 144 Voss L, Lennon D, Okesene-Gafa K, Ameratunga S, Martin D. Invasive pneumococcal disease in a pediatric population, Auckland, New Zealand.  Pediatr Infect Dis J. 1994;  13 873-878
• 145 Fraser D, Givon-Lavi N, Bilenko N, Dagan R. A decade (1989–1998) of pediatric invasive pneumococcal disease in 2 populations residing in 1 geographic location: implications for vaccine choice.  Clin Infect Dis. 2001;  33 421-427
• 146 Roy S, Knox K, Segal S et al.. MBL genotype and risk of invasive pneumococcal disease: a case-control study.  Lancet. 2002;  359 1569-1573
• 147 Yee A M, Phan H M, Zuniga R, Salmon J E, Musher D M. Association between FcgammaRIIa-R131 allotype and bacteremic pneumococcal pneumonia.  Clin Infect Dis. 2000;  30 25-28
• 148 Moens L, Van Hoeyveld E, Peetermans W E, De Boeck C, Verhaegen J, Bossuyt X. Mannose-binding lectin genotype and invasive pneumococcal infection.  Hum Immunol. 2006;  67 605-611
• 149 Schaaf B M, Boehmke F, Esnaashari H et al.. Pneumococcal septic shock is associated with the interleukin-10–1082 gene promoter polymorphism.  Am J Respir Crit Care Med. 2003;  168 476-480
• 150 Burman L A, Norrby R, Trollfors B. Invasive pneumococcal infections: incidence, predisposing factors, and prognosis.  Rev Infect Dis. 1985;  7 133-142
• 151 Pastor P, Medley F, Murphy T V. Invasive pneumococcal disease in Dallas County, Texas: results from population-based surveillance in 1995.  Clin Infect Dis. 1998;  26 590-595
• 152 Davidson M, Parkinson A J, Bulkow L R, Fitzgerald M A, Peters H V, Parks D J. The epidemiology of invasive pneumococcal disease in Alaska, 1986–1990–ethnic differences and opportunities for prevention.  J Infect Dis. 1994;  170 368-376
• 153 Lipsky B A, Boyko E J, Inui T S, Koepsell T D. Risk factors for acquiring pneumococcal infections.  Arch Intern Med. 1986;  146 2179-2185
• 154 Nuorti J P, Butler J C, Farley M M et al.. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team.  N Engl J Med. 2000;  342 681-689
• 155 Talbot T R, Hartert T V, Mitchel E et al.. Asthma as a risk factor for invasive pneumococcal disease.  N Engl J Med. 2005;  352 2082-2090
• 156 O'Brien K L, Walters M I, Sellman J et al.. Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection.  Clin Infect Dis. 2000;  30 784-789
• 157 Thomsen R W, Hundborg H H, Lervang H H, Johnsen S P, Schonheyder H C, Sorensen H T. Risk of community-acquired pneumococcal bacteremia in patients with diabetes: a population-based case-control study.  Diabetes Care. 2004;  27 1143-1147
• 158 Loeb M. Pneumonia in older persons.  Clin Infect Dis. 2003;  37 1335-1339
• 159 Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among post-splenectomy patients.  J Infect. 2001;  43 182-186
• 160 Schutze G E, Mason Jr E O, Barson W J et al.. Invasive pneumococcal infections in children with asplenia.  Pediatr Infect Dis J. 2002;  21 278-282
• 161 Gilbert B, Menetrey C, Belin V, Brosset P, de Lumley L, Fisher A. Familial isolated congenital asplenia: a rare, frequently hereditary dominant condition, often detected too late as a cause of overwhelming pneumococcal sepsis. Report of a new case and review of 31 others.  Eur J Pediatr. 2002;  161 368-372
• 162 Halasa N B, Shankar S M, Talbot T R et al.. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine.  Clin Infect Dis. 2007;  44 1428-1433
• 163 Wong W Y, Overturf G D, Powars D R. Infection caused by Streptococcus pneumoniae in children with sickle cell disease: epidemiology, immunologic mechanisms, prophylaxis, and vaccination.  Clin Infect Dis. 1992;  14 1124-1136
• 164 Adamkiewicz T V, Sarnaik S, Buchanan G R et al.. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination.  J Pediatr. 2003;  143 438-444
• 165 Carratala J, Roson B, Fernandez-Sevilla A, Alcaide F, Gudiol F. Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome.  Arch Intern Med. 1998;  158 868-872
• 166 Kumashi P, Girgawy E, Tarrand J J, Rolston K V, Raad I I, Safdar A. Streptococcus pneumoniae bacteremia in patients with cancer: disease characteristics and outcomes in the era of escalating drug resistance (1998–2002).  Medicine (Baltimore). 2005;  84 303-312
• 167 Chou M Y, Brown A E, Blevins A, Armstrong D. Severe pneumococcal infection in patients with neoplastic disease.  Cancer. 1983;  51 1546-1550
• 168 Youssef S, Rodriguez G, Rolston K V, Champlin R E, Raad I I, Safdar A. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989–2005.  Medicine (Baltimore). 2007;  86 69-77
• 169 Castagnola E, Fioredda F. Prevention of life-threatening infections due to encapsulated bacteria in children with hyposplenia or asplenia: a brief review of current recommendations for practical purposes.  Eur J Haematol. 2003;  71 319-326
• 170 Altamura M, Caradonna L, Amati L, Pellegrino N M, Urgesi G, Miniello S. Splenectomy and sepsis: the role of the spleen in the immune-mediated bacterial clearance.  Immunopharmacol Immunotoxicol. 2001;  23 153-161
• 171 Schutze G E, Mason Jr E O, Wald E R et al.. Pneumococcal infections in children after transplantation.  Clin Infect Dis. 2001;  33 16-21
• 172 Kumar D, Humar A, Plevneshi A et al.. Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance.  Bone Marrow Transplant. 2008;  41 743-747
• 173 Engelhard D, Cordonnier C, Shaw P J et al.. Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey.  Br J Haematol. 2002;  117 444-450
• 174 Redd S C, Rutherford III G W, Sande M A et al.. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents.  J Infect Dis. 1990;  162 1012-1017
• 175 King M D, Whitney C G, Parekh F, Farley M M. Recurrent invasive pneumococcal disease: a population-based assessment.  Clin Infect Dis. 2003;  37 1029-1036
• 176 Coccia M R, Facklam R R, Saravolatz L D, Manzor O. Recurrent pneumococcal bacteremia: 34 episodes in 15 patients.  Clin Infect Dis. 1998;  26 982-985
• 177 Font B, Lliminana C, Fontanals D, Pineda V, Segura F. Eleven-year study of recurrent pneumococcal bacteremia.  Eur J Clin Microbiol Infect Dis. 2001;  20 636-638
• 178 Barrett-Connor E. Bacterial infection and sickle cell anemia. An analysis of 250 infections in 166 patients and a review of the literature.  Medicine (Baltimore). 1971;  50 97-112
• 179 Adamkiewicz T V, Silk B J, Howgate J et al.. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.  Pediatrics. 2008;  121 562-569
• 180 Chesney P J, Wilimas J A, Presbury G et al.. Penicillin- and cephalosporin-resistant strains of Streptococcus pneumoniae causing sepsis and meningitis in children with sickle cell disease.  J Pediatr. 1995;  127 526-532
• 181 Hord J, Byrd R, Stowe L, Windsor B, Smith-Whitley K. Streptococcus pneumoniae sepsis and meningitis during the penicillin prophylaxis era in children with sickle cell disease.  J Pediatr Hematol Oncol. 2002;  24 470-472
• 182 Powars D R, Chan L S, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients.  Medicine (Baltimore). 2005;  84 363-376
• 183 Miller S T, Sleeper L A, Pegelow C H et al.. Prediction of adverse outcomes in children with sickle cell disease.  N Engl J Med. 2000;  342 83-89
• 184 Leikin S L, Gallagher D, Kinney T R, Sloane D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease.  Pediatrics. 1989;  84 500-508
• 185 Knight-Madden J, Serjeant G R. Invasive pneumococcal disease in homozygous sickle cell disease: Jamaican experience 1973–1997.  J Pediatr. 2001;  138 65-70
• 186 Gaston M H, Verter J I, Woods G et al.. Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial.  N Engl J Med. 1986;  314 1593-1599
• 187 Quinn C T, Rogers Z R, Buchanan G R. Survival of children with sickle cell disease.  Blood. 2004;  103 4023-4027
• 188 Sox C M, Cooper W O, Koepsell T D, DiGiuseppe D L, Christakis D A. Provision of pneumococcal prophylaxis for publicly insured children with sickle cell disease.  JAMA. 2003;  290 1057-1061
• 189 O'Brien K L, Swift A J, Winkelstein J A et al.. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group.  Pediatrics. 2000;  106 965-972
• 190 Reinert P, Benkerrou M, de Montalembert M et al.. Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease.  Pediatr Infect Dis J. 2007;  26(12) 1105-1109
• 191 Vernacchio L, Neufeld E J, MacDonald K et al.. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease.  J Pediatr. 1998;  133 275-278
• 192 Wong W Y, Powars D R, Chan L, Hiti A, Johnson C, Overturf G. Polysaccharide encapsulated bacterial infection in sickle cell anemia: a thirty year epidemiologic experience.  Am J Hematol. 1992;  39 176-182
• 193 Falletta J M, Woods G M, Verter J I et al.. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II.  J Pediatr. 1995;  127 685-690
• 194 American Academy of Pediatrics . Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis.  Pediatrics. 2000;  106(2 Pt 1) 362-366
• 195 Kizito M E, Mworozi E, Ndugwa C, Serjeant G R. Bacteraemia in homozygous sickle cell disease in Africa: is pneumococcal prophylaxis justified?.  Arch Dis Child. 2007;  92 21-23
• 196 Chilcote R R, Baehner R L, Hammond D. Septicemia and meningitis in children splenectomized for Hodgkin's disease.  N Engl J Med. 1976;  295 798-800
• 197 Foss Abrahamsen A, Hoiby E A, Hannisdal E et al.. Systemic pneumococcal disease after staging splenectomy for Hodgkin's disease 1969–1980 without pneumococcal vaccine protection: a follow-up study 1994.  Eur J Haematol. 1997;  58 73-77
• 198 Konradsen H B, Henrichsen J. Pneumococcal infections in splenectomized children are preventable.  Acta Paediatr Scand. 1991;  80 423-427
• 199 Waldman J D, Rosenthal A, Smith A L, Shurin S, Nadas A S. Sepsis and congenital asplenia.  J Pediatr. 1977;  90 555-559
• 200 Meisel R, Toschke A M, Heiligensetzer C, Dilloo D, Laws H J, von Kries R. Increased risk for invasive pneumococcal diseases in children with acute lymphoblastic leukaemia.  Br J Haematol. 2007;  137 457-460
• 201 Amber I J, Gilbert E M, Schiffman G, Jacobson J A. Increased risk of pneumococcal infections in cardiac transplant recipients.  Transplantation. 1990;  49 122-125
• 202 Haddad P A, Repka T L, Weisdorf D J. Penicillin-resistant Streptococcus pneumoniae septic shock and meningitis complicating chronic graft versus host disease: a case report and review of the literature.  Am J Med. 2002;  113 152-155
• 203 Kulkarni S, Powles R, Treleaven J et al.. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants.  Blood. 2000;  95 3683-3686
• 204 Rege K, Mehta J, Treleaven J et al.. Fatal pneumococcal infections following allogeneic bone marrow transplant.  Bone Marrow Transplant. 1994;  14 903-906
• 205 Kumar D, Humar A, Plevneshi A et al.. Invasive pneumococcal disease in solid organ transplant recipients–10-year prospective population surveillance.  Am J Transplant. 2007;  7 1209-1214
• 206 Rizzo J D, Wingard J R, Tichelli A et al.. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation.  Biol Blood Marrow Transplant. 2006;  12 138-151
• 207 Ljungman P, Engelhard D, de la Camara R et al.. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT.  Bone Marrow Transplant. 2005;  35 737-746
• 208 Nordoy T, Husebekk A, Aaberge I S et al.. Humoral immunity to viral and bacterial antigens in lymphoma patients 4–10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines.  Bone Marrow Transplant. 2001;  28 681-687
• 209 Molrine D C, Antin J H, Guinan E C et al.. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation.  Blood. 2003;  101 831-836
• 210 Jordano Q, Falco V, Almirante B et al.. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy.  Clin Infect Dis. 2004;  38 1623-1628
• 211 Nuorti J P, Butler J C, Gelling L, Kool J L, Reingold A L, Vugia D J. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California.  Ann Intern Med. 2000;  132 182-190
• 212 Dworkin M S, Ward J W, Hanson D L, Jones J L, Kaplan J E. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination.  Clin Infect Dis. 2001;  32 794-800
• 213 Frankel R E, Virata M, Hardalo C, Altice F L, Friedland G. Invasive pneumococcal disease: clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection.  Clin Infect Dis. 1996;  23 577-584
• 214 Boschini A, Smacchia C, Di Fine M et al.. Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: incidence, etiologies, and clinical aspects.  Clin Infect Dis. 1996;  23 107-113
• 215 Bliss S J, O'Brien K L, Janoff E N et al.. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease.  Lancet Infect Dis. 2008;  8 67-80
• 216 Dankner W M, Lindsey J C, Levin M J. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy.  Pediatr Infect Dis J. 2001;  20 40-48
• 217 Madhi S A, Petersen K, Madhi A, Wasas A, Klugman K P. Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children.  Pediatr Infect Dis J. 2000;  19 1141-1147
• 218 Madhi S A, Petersen K, Madhi A, Khoosal M, Klugman K P. Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children.  Clin Infect Dis. 2000;  31 170-176
• 219 Laufer M K, van Oosterhout J J, Perez M A et al.. Observational cohort study of HIV-infected African children.  Pediatr Infect Dis J. 2006;  25 623-627
• 220 Gill C J, Mwanakasale V, Fox M P et al.. Impact of human immunodeficiency virus infection on Streptococcus pneumoniae colonization and seroepidemiology among Zambian women.  J Infect Dis. 2008;  197 1000-1005
• 221 Fry A M, Facklam R R, Whitney C G, Plikaytis B D, Schuchat A. Multistate evaluation of invasive pneumococcal diseases in adults with human immunodeficiency virus infection: serotype and antimicrobial resistance patterns in the United States.  J Infect Dis. 2003;  188 643-652
• 222 Heffernan R T, Barrett N L, Gallagher K M et al.. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995–2000.  J Infect Dis. 2005;  191 2038-2045
• 223 Lopez-Palomo C, Martin-Zamorano M, Benitez E et al.. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.  J Med Virol. 2004;  72 517-524
• 224 Grau I, Pallares R, Tubau F et al.. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.  Arch Intern Med. 2005;  165 1533-1540
• 225 Gona P, Van Dyke R B, Williams P L et al.. Incidence of opportunistic and other infections in HIV-infected children in the HAART era.  JAMA. 2006;  296 292-300
• 226 Viani R M, Araneta M R, Deville J G, Spector S A. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.  Clin Infect Dis. 2004;  39 725-731
• 227 Nachman S, Gona P, Dankner W et al.. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.  Pediatrics. 2005;  115 e488-e494
• 228 Karstaedt A S, Khoosal M, Crewe-Brown H H. Pneumococcal bacteremia in adults in Soweto, South Africa, during the course of a decade.  Clin Infect Dis. 2001;  33 610-614
• 229 Almirante B, Saballs M, Ribera E et al.. Favorable prognosis of purulent meningitis in patients infected with human immunodeficiency virus.  Clin Infect Dis. 1998;  27 176-180
• 230 Janoff E N, O'Brien J, Thompson P et al.. Streptococcus pneumoniae colonization, bacteremia, and immune response among persons with human immunodeficiency virus infection.  J Infect Dis. 1993;  167 49-56
• 231 Crewe-Brown H H, Karstaedt A S, Saunders G L et al.. Streptococcus pneumoniae blood culture isolates from patients with and without human immunodeficiency virus infection: alterations in penicillin susceptibilities and in serogroups or serotypes.  Clin Infect Dis. 1997;  25 1165-1172
• 232 Wininger D A, Fass R J. Impact of trimethoprim-sulfamethoxazole prophylaxis on etiology and susceptibilities of pathogens causing human immunodeficiency virus-associated bacteremia.  Antimicrob Agents Chemother. 2002;  46 594-597
• 233 Masur H, Kaplan J E, Holmes K K. Guidelines for preventing opportunistic infections among HIV-infected persons–2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America.  Ann Intern Med. 2002;  137(5 Pt 2) 435-478
• 234 Amendola A, Tanzi E, Zappa A et al.. Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users.  Vaccine. 2002;  20 3720-3724
• 235 Huo Z, Miles J, Harris T, Riches P. Effect of Pneumovax II vaccination in high-risk individuals on specific antibody and opsonic capacity against specific and non-specific antigen.  Vaccine. 2002;  20 3532-3534
• 236 French N, Gilks C F, Mujugira A, Fasching C, O'Brien J, Janoff E N. Pneumococcal vaccination in HIV-1-infected adults in Uganda: humoral response and two vaccine failures.  AIDS. 1998;  12 1683-1689
• 237 French N, Nakiyingi J, Carpenter L M et al.. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial.  Lancet. 2000;  355 2106-2111
• 238 Gebo K A, Moore R D, Keruly J C, Chaisson R E. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients.  J Infect Dis. 1996;  173 857-862
• 239 Rodriguez-Barradas M C, Goulet J, Brown S et al.. Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study.  Clin Infect Dis. 2008;  46 1093-1100
• 240 Moir S, Ogwaro K M, Malaspina A et al.. Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals.  Proc Natl Acad Sci U S A. 2003;  100 6057-6062
• 241 Rodriguez-Barradas M C, Alexandraki I, Nazir T et al.. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine.  Clin Infect Dis. 2003;  37 438-447
• 242 Feikin D R, Elie C M, Goetz M B et al.. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults.  Vaccine. 2001;  20 545-553
• 243 Kroon F P, van Dissel J T, Ravensbergen E, Nibbering P H, van Furth R. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults.  Vaccine. 2000;  19 886-894
• 244 Nachman S, Kim S, King J et al.. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection.  Pediatrics. 2003;  112(1 Pt 1) 66-73
• 245 Abzug M J, Pelton S I, Song L Y et al.. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.  Pediatr Infect Dis J. 2006;  25 920-929
• 246 Spoulou V I, Tsoumas D L, Papaevangelou V G, Mostrou G I, Theodoridou M C. Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children.  Vaccine. 2005;  23 5289-5293
• 247 Madhi S A, Kuwanda L, Cutland C, Holm A, Kayhty H, Klugman K P. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children.  Pediatr Infect Dis J. 2005;  24 410-416
• 248 Klugman K P, Madhi S A, Huebner R E, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.  N Engl J Med. 2003;  349 1341-1348
• 249 Madhi S A, Adrian P, Kuwanda L et al.. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine.  Vaccine. 2007;  25 2451-2457
• 250 Laurichesse H, Romaszko J P, Nguyen L T et al.. Clinical characteristics and outcome of patients with invasive pneumococcal disease, Puy-de-Dome, France, 1994–1998.  Eur J Clin Microbiol Infect Dis. 2001;  20 299-308
• 251 Tsai C J, Griffin M R, Pekka Nuorti J, Grijalva C G. Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States.  Clin Infect Dis. 2008;  46 1664-1672
• 252 Hook III E W, Horton C A, Schaberg D R. Failure of intensive care unit support to influence mortality from pneumococcal bacteremia.  JAMA. 1983;  249 1055-1057
• 253 Farinas-Alvarez C, Farinas M C, Garcia-Palomo J D et al.. Prognostic factors for pneumococcal bacteremia in a university hospital.  Eur J Clin Microbiol Infect Dis. 2000;  19 733-741
• 254 Lujan M, Gallego M, Fontanals D, Mariscal D, Rello J. Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality.  Crit Care Med. 2004;  32 625-631
• 255 Torres J M, Cardenas O, Vasquez A, Schlossberg D. Streptococcus pneumoniae bacteremia in a community hospital.  Chest. 1998;  113 387-390
• 256 Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia.  Ann Intern Med. 1964;  60 759-776
• 257 Perlino C A, Rimland D. Alcoholism, leukopenia, and pneumococcal sepsis.  Am Rev Respir Dis. 1985;  132 757-760
• 258 Metlay J P, Hofmann J, Cetron M S et al.. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia.  Clin Infect Dis. 2000;  30 520-528
• 259 Rothermel C D. Penicillin and macrolide resistance in pneumococcal pneumonia: does in vitro resistance affect clinical outcomes?.  Clin Infect Dis. 2004;  38(Suppl 4) S346-S349
• 260 Aspa J, Rajas O, Rodriguez de Castro F et al.. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors.  Clin Infect Dis. 2004;  38 787-798
• 261 Calbo E, Diaz A, Canadell E et al.. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine.  Clin Microbiol Infect. 2006;  12 867-872
• 262 Lin C J, Chen P Y, Huang F L, Lee T, Chi C S, Lin C Y. Radiographic, clinical, and prognostic features of complicated and uncomplicated community-acquired lobar pneumonia in children.  J Microbiol Immunol Infect. 2006;  39 489-495
• 263 Ramphul N, Eastham K M, Freeman R et al.. Cavitatory lung disease complicating empyema in children.  Pediatr Pulmonol. 2006;  41 750-753
• 264 Hsieh Y C, Hsiao C H, Tsao P N et al.. Necrotizing pneumococcal pneumonia in children: the role of pulmonary gangrene.  Pediatr Pulmonol. 2006;  41 623-629
• 265 Eastham K M, Freeman R, Kearns A M et al.. Clinical features, aetiology and outcome of empyema in children in the north east of England.  Thorax. 2004;  59 522-525
• 266 Byington C L, Samore M H, Stoddard G J et al.. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups.  Clin Infect Dis. 2005;  41 21-29
• 267 Werno A M, Murdoch D R. Medical microbiology: laboratory diagnosis of invasive pneumococcal disease.  Clin Infect Dis. 2008;  46 926-932
• 268 Roson B, Carratala J, Verdaguer R, Dorca J, Manresa F, Gudiol F. Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization.  Clin Infect Dis. 2000;  31 869-874
• 269 Marcos M A, Jimenez de Anta M T, de la Bellacasa J P et al.. Rapid urinary antigen test for diagnosis of pneumococcal community-acquired pneumonia in adults.  Eur Respir J. 2003;  21 209-214
• 270 Murdoch D R, Laing R T, Mills G D et al.. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia.  J Clin Microbiol. 2001;  39 3495-3498
• 271 Samra Z, Shmuely H, Nahum E, Paghis D, Ben-Ari J. Use of the NOW Streptococcus pneumoniae urinary antigen test in cerebrospinal fluid for rapid diagnosis of pneumococcal meningitis.  Diagn Microbiol Infect Dis. 2003;  45 237-240
• 272 Le Monnier A, Carbonnelle E, Zahar J R et al.. Microbiological diagnosis of empyema in children: comparative evaluations by culture, polymerase chain reaction, and pneumococcal antigen detection in pleural fluids.  Clin Infect Dis. 2006;  42 1135-1140
• 273 Roson B, Fernandez-Sabe N, Carratala J et al.. Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia.  Clin Infect Dis. 2004;  38 222-226
• 274 Hamer D H, Egas J, Estrella B, MacLeod W B, Griffiths J K, Sempertegui F. Assessment of the Binax NOW Streptococcus pneumoniae urinary antigen test in children with nasopharyngeal pneumococcal carriage.  Clin Infect Dis. 2002;  34 1025-1028
• 275 Adegbola R A, Obaro S K, Biney E, Greenwood B M. Evaluation of Binax now Streptococcus pneumoniae urinary antigen test in children in a community with a high carriage rate of pneumococcus.  Pediatr Infect Dis J. 2001;  20 718-719
• 276 Dowell S F, Garman R L, Liu G, Levine O S, Yang Y H. Evaluation of Binax NOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients.  Clin Infect Dis. 2001;  32 824-825
• 277 Fedson D S. Pneumococcal vaccination in the United States and 20 other developed countries, 1981–1996.  Clin Infect Dis. 1998;  26 1117-1123
• 278 Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 1997;  46(RR-8) 1-24
• 279 Sisk J E, Moskowitz A J, Whang W et al.. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people.  JAMA. 1997;  278 1333-1339
• 280 Shapiro E D, Berg A T, Austrian R et al.. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.  N Engl J Med. 1991;  325 1453-1460
• 281 Butler J C, Breiman R F, Campbell J F, Lipman H B, Broome C V, Facklam R R. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations.  JAMA. 1993;  270 1826-1831
• 282 Honkanen P O, Keistinen T, Miettinen L et al.. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older.  Vaccine. 1999;  17 2493-2500
• 283 Ortqvist A, Hedlund J, Burman L A et al.. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group.  Lancet. 1998;  351 399-403
• 284 Breiman R F, Keller D W, Phelan M A et al.. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients.  Arch Intern Med. 2000;  160 2633-2638
• 285 Jackson L A, Neuzil K M, Yu O et al.. Effectiveness of pneumococcal polysaccharide vaccine in older adults.  N Engl J Med. 2003;  348 1747-1755
• 286 Simberkoff M S, Cross A P, Al-Ibrahim M et al.. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study.  N Engl J Med. 1986;  315 1318-1327
• 287 Watson L, Wilson B J, Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults.  Vaccine. 2002;  20 2166-2173
• 288 Brandao A P, de Oliveira T C, de Cunto Brandileone M C, Goncalves J E, Yara T I, Simonsen V. Persistence of antibody response to pneumococcal capsular polysaccharides in vaccinated long term-care residents in Brazil.  Vaccine. 2004;  23 762-768
• 289 Rubins J B, Puri A K, Loch J et al.. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults.  J Infect Dis. 1998;  178 431-440
• 290 Konradsen H B. Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons.  Clin Infect Dis. 1995;  21 616-620
• 291 Pebody R G, Leino T, Nohynek H, Hellenbrand W, Salmaso S, Ruutu P. Pneumococcal vaccination policy in Europe.  Euro Surveill. 2005;  10 174-178
• 292 Torling J, Hedlund J, Konradsen H B, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia.  Vaccine. 2003;  22 96-103
• 293 Willis B C, Ndiaye S M, Hopkins D P, Shefer A. Improving influenza, pneumococcal polysaccharide, and hepatitis B vaccination coverage among adults aged < 65 years at high risk: a report on recommendations of the Task Force on Community Preventive Services.  MMWR Recomm Rep. 2005;  54(RR-5) 1-11
• 294 Jackson L A, Neuzil K M, Nahm M H et al.. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.  Vaccine. 2007;  25 4029-4037
• 295 Jackson L A, Benson P, Sneller V P et al.. Safety of revaccination with pneumococcal polysaccharide vaccine.  JAMA. 1999;  281 243-248
• 296 Kyaw M H, Greene C M, Schaffner W et al.. Adults with invasive pneumococcal disease: missed opportunities for vaccination.  Am J Prev Med. 2006;  31 286-292
• 297 Advisory Committee on Immunization Practice . Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practice (ACIP).  MMWR Recomm Rep. 2000;  49(RR-9) 1-35
• 298 Shinefield H R, Black S, Ray P et al.. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.  Pediatr Infect Dis J. 1999;  18 757-763
• 299 Black S, Shinefield H, Fireman B et al.. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.  Pediatr Infect Dis J. 2000;  19 187-195
• 300 Pelton S I. Replacement pneumococcal disease in perspective.  Clin Infect Dis. 2008;  46 1353-1355
• 301 Feikin D R, Klugman K P, Facklam R R, Zell E R, Schuchat A, Whitney C G. Increased prevalence of pediatric pneumococcal serotypes in elderly adults.  Clin Infect Dis. 2005;  41 481-487
• 302 Updated Recommendations from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 24–59 months who are not completed vaccinated.  MMWR Morb Mortal Wkly Rep. 2008;  57 343-344
• 303 Reinert P, Guy M, Girier B et al.. The safety and immunogenicity of an heptavalent pneumococcal polysaccharide conjugate vaccine (Prevenar) administered in association with a whole-cell pertussis-based pediatric combination vaccine (DTP-IPV/PRP-T) to French infants with a two-, three-, and four-month schedule [in French].  Arch Pediatr. 2003;  10 1048-1055
• 304 Cutts F T, Zaman S M, Enwere G et al.. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: randomised, double-blind, placebo-controlled trial.  Lancet. 2005;  365 1139-1146
• 305 Lipsitch M, O'Neill K, Cordy D et al.. Strain characteristics of Streptococcus pneumoniae carriage and invasive disease isolates during a cluster-randomized clinical trial of the 7-valent pneumococcal conjugate vaccine.  J Infect Dis. 2007;  196 1221-1227
• 306 Poehling K A, Talbot T R, Griffin M R et al.. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine.  JAMA. 2006;  295 1668-1674
• 307 Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease–United States, 1998–2003.  MMWR Morb Mortal Wkly Rep. 2005;  54(36) 893-897
• 308 Black S B, Shinefield H R, Hansen J, Elvin L, Laufer D, Malinoski F. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine.  Pediatr Infect Dis J. 2001;  20 1105-1107
• 309 Kellner J D, Church D L, MacDonald J, Tyrrell G J, Scheifele D. Progress in the prevention of pneumococcal infection.  CMAJ. 2005;  173 1149-1151
• 310 Steenhoff A P, Shah S S, Ratner A J, Patil S M, McGowan K L. Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia.  Clin Infect Dis. 2006;  42 907-914
• 311 Cohen R, Levy C, de La Rocque F et al.. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media.  Pediatr Infect Dis J. 2006;  25 1001-1007
• 312 Hammitt L L, Bruden D L, Butler J C et al.. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease.  J Infect Dis. 2006;  193 1487-1494
• 313 Eskola J, Kilpi T, Palmu A et al.. Efficacy of a pneumococcal conjugate vaccine against acute otitis media.  N Engl J Med. 2001;  344 403-409
• 314 Porat N, Arguedas A, Spratt B G et al.. Emergence of penicillin-nonsusceptible Streptococcus pneumoniae clones expressing serotypes not present in the antipneumococcal conjugate vaccine.  J Infect Dis. 2004;  190 2154-2161
• 315 de Roux A, Schmoele-Thoma B, Siber G R et al.. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.  Clin Infect Dis. 2008;  46 1015-1023
• 316 Nichol K L, Margolis K L, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community.  N Engl J Med. 1994;  331 778-784
• 317 Gross P A, Hermogenes A W, Sacks H S, Lau J, Levandowski R A. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature.  Ann Intern Med. 1995;  123 518-527
• 318 Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons.  Eur Respir J. 2004;  23 363-368